Revenue and net loss improved year-over-year, with a sharpened focus on early diagnostics and clinical applications. A fully guaranteed rights issue is underway to secure funding, while new partnerships, patent filings, and international exposure support long-term growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.